These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin. Moreira CG; Barbiero JK; Ariza D; Dombrowski PA; Sabioni P; Bortolanza M; Da Cunha C; Vital MA; Lima MM Neurotox Res; 2012 Apr; 21(3):291-301. PubMed ID: 21953489 [TBL] [Abstract][Full Text] [Related]
4. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Betarbet R; Canet-Aviles RM; Sherer TB; Mastroberardino PG; McLendon C; Kim JH; Lund S; Na HM; Taylor G; Bence NF; Kopito R; Seo BB; Yagi T; Yagi A; Klinefelter G; Cookson MR; Greenamyre JT Neurobiol Dis; 2006 May; 22(2):404-20. PubMed ID: 16439141 [TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776 [TBL] [Abstract][Full Text] [Related]
7. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. Tapias V; Cannon JR; Greenamyre JT J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169 [TBL] [Abstract][Full Text] [Related]
8. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. Zharikov AD; Cannon JR; Tapias V; Bai Q; Horowitz MP; Shah V; El Ayadi A; Hastings TG; Greenamyre JT; Burton EA J Clin Invest; 2015 Jul; 125(7):2721-35. PubMed ID: 26075822 [TBL] [Abstract][Full Text] [Related]
9. Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration study. Zhang ZN; Zhang JS; Xiang J; Yu ZH; Zhang W; Cai M; Li XT; Wu T; Li WW; Cai DF Brain Res; 2017 Jan; 1655():104-113. PubMed ID: 27876560 [TBL] [Abstract][Full Text] [Related]
10. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease. Carriere CH; Kang NH; Niles LP Brain Res; 2016 Feb; 1633():115-125. PubMed ID: 26740407 [TBL] [Abstract][Full Text] [Related]
11. Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. Pierre SR; Lemmens MA; Figueiredo-Pereira ME J Neuroinflammation; 2009 Jul; 6():18. PubMed ID: 19630993 [TBL] [Abstract][Full Text] [Related]
12. Environment-contact administration of rotenone: A new rodent model of Parkinson's disease. Liu Y; Sun JD; Song LK; Li J; Chu SF; Yuan YH; Chen NH Behav Brain Res; 2015 Nov; 294():149-61. PubMed ID: 26239001 [TBL] [Abstract][Full Text] [Related]
13. The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings. von Wrangel C; Schwabe K; John N; Krauss JK; Alam M Behav Brain Res; 2015 Feb; 279():52-61. PubMed ID: 25446762 [TBL] [Abstract][Full Text] [Related]
14. Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. Inden M; Kitamura Y; Abe M; Tamaki A; Takata K; Taniguchi T Biol Pharm Bull; 2011; 34(1):92-6. PubMed ID: 21212524 [TBL] [Abstract][Full Text] [Related]
15. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Alam M; Schmidt WJ Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640 [TBL] [Abstract][Full Text] [Related]
17. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Betarbet R; Sherer TB; MacKenzie G; Garcia-Osuna M; Panov AV; Greenamyre JT Nat Neurosci; 2000 Dec; 3(12):1301-6. PubMed ID: 11100151 [TBL] [Abstract][Full Text] [Related]
18. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
19. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. Alam M; Danysz W; Schmidt WJ; Dekundy A Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571 [TBL] [Abstract][Full Text] [Related]
20. α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment. George S; Mok SS; Nurjono M; Ayton S; Finkelstein DI; Masters CL; Li QX; Culvenor JG J Mol Neurosci; 2010 Oct; 42(2):243-54. PubMed ID: 20464527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]